Last reviewed · How we verify

Myalept — Competitive Intelligence Brief

Myalept (METRELEPTIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leptin Analog [EPC]. Area: Metabolic.

marketed Leptin Analog [EPC] Leptin receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Myalept (METRELEPTIN) — Amylin Pharms Llc. Myalept works by mimicking the action of leptin, a hormone that regulates fat distribution and metabolism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Myalept TARGET METRELEPTIN Amylin Pharms Llc marketed Leptin Analog [EPC] Leptin receptor 2014-01-01
LEP LEP Bayer marketed Leptin receptor agonist Leptin receptor (OB-R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leptin Analog [EPC] class)

  1. Amylin Pharms Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Myalept — Competitive Intelligence Brief. https://druglandscape.com/ci/metreleptin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: